Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study Meeting Abstract
| Authors: | Kelly, W. K.; Appleman, L. J.; Lin, C. C.; Armstrong, A. J.; Fischer, S. C.; Pook, D. W.; Perez Gracia, J. L.; Lee, J. L.; Berthold, D. R.; Ward, P. J.; Castellano Gauna, D. E.; Horvath, L. G.; Kim, M.; Matsubara, N.; Sumey, C.; Shabooti, M.; Yang, Z.; Connarn, J.; Stieglmaier, J.; Danila, D. C. |
| Abstract Title: | Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S963 |
| End Page: | S964 |
| Language: | English |
| ACCESSION: | WOS:001326612902220 |
| DOI: | 10.1016/j.annonc.2024.08.1679 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1598P -- Source: Wos |
